Altimmune, Inc. (ALT) |
|
4.32 0.13 (3.1%)
|
03-24 16:00 |
|
Open: |
4.23 |
Pre. Close: |
4.19 |
|
High:
|
4.43 |
Low:
|
4.19 |
|
Volume:
|
3,666,821 |
Market Cap:
|
213(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:56 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 11.01 One year: 14.83 |
| Support: |
Support1: 4.13 Support2: 3.44 |
| Resistance: |
Resistance1: 9.43 Resistance2: 12.69 |
| Pivot: |
9.23  |
| Moving Average: |
MA(5): 5.71 MA(20): 9.9
MA(100): 11.99 MA(250): 11.12 |
| MACD: |
MACD(12,26): -2 Signal(9): -1.2 |
| Stochastic oscillator: |
%K(14,3): 1.1  %D(3): 4.5 |
| RSI: |
RSI(14): 17.6 |
| 52-week: |
High: 23.48 Low: 3.82 |
| Average Vol(K): |
3-Month: 1,773 (K) 10-Days: 4,506 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALT ] has closed above bottom band by 8.0%. Bollinger Bands are 177.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.44 - 4.47 |
4.47 - 4.5 |
|
Low:
|
4.12 - 4.16 |
4.16 - 4.19 |
|
Close:
|
4.26 - 4.32 |
4.32 - 4.37 |
|
Company Description |
|
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. |
Headline News |
Wed, 22 Mar 2023
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data - Nasdaq
Tue, 21 Mar 2023
Altimmune Inc. (ALT stock) - Bad Drug Trial News Weighs it Down - The Coin Republic
Tue, 21 Mar 2023
Healthcare Stocks Moving Tuesday: QNCX, DRMA, IBRX, NCNA, ALT, CHEK, ROIVW, ATNX - InvestorsObserver
Tue, 21 Mar 2023
Altimmune's obesity drug safety concerns shrink shares - Reuters.com
Tue, 14 Mar 2023
Q1 2023 EPS Estimates for Altimmune, Inc. (NASDAQ:ALT) Analyst's ... - Best Stocks
Tue, 14 Mar 2023
Two Sigma Advisers LP Raises Stock Position in Altimmune, Inc ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
49 (M) |
|
% Held by Insiders
|
3.959e+007 (%) |
|
% Held by Institutions
|
0.8 (%) |
|
Shares Short
|
6,170 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-8.761e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
128 |
|
Return on Assets (ttm)
|
902.9 |
|
Return on Equity (ttm)
|
-25.8 |
|
Qtrly Rev. Growth
|
-68000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-489.67 |
|
EBITDA (p.s.)
|
-7.83556e+008 |
|
Qtrly Earnings Growth
|
-1.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-63 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.1 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
6.38e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-09-13 |
|
Ex-Dividend Date
|
2017-01-19 |
|
Your Ad Here
|
|
